News
Merck Inc. cancels its SARS-CoV-2/COVID-19 vaccine candidates, V 590 and V 591 and focuses on MK 7110 and MK 4482.
Merck Inc.,, known as MSD outside the United States and Canada, announced that the company is discontinuing development of its SARS-CoV-2/COVID-19 vaccine candidates, V 590 and V 591, and plans to focus its SARS-CoV-2/COVID-19 research strategy and production capabilities on advancing two therapeutic candidates, MK 4482 and MK 7110.
This decision follows Merck’s review of findings from Phase 1 clinical studies for the vaccines. In these studies, both V 590 and V 591 were generally well tolerated, but the immune responses were inferior to those seen following natural infection and those reported for other SARS-CoV-2/COVID-19 vaccines.
Merck continues to advance clinical programs and to scale-up manufacturing for two investigational medicines, MK 7110 and MK 4482 (molnupiravir); molnupiravir is being developed in collaboration with Ridgeback Bio.
Condition: Coronavirus/COVID-19 Infection
Type: drug
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins